

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

Under the Securities Exchange Act of 1934

Ribozyme Pharmaceuticals, Inc.

(Name of Issuer)

Common Stock, \$.01 Par Value

(Title of Class of Securities)

76256710-5
(CUSIP Number)

N/A

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this
Schedule is filed:

Rule 13d-1(b)

X Rule 13d-1(c)

Rule 13d-1(d)

*The remainder of this cover page shall be filled out for a reporting
person's initial filing on this form with respect to the subject class of
securities, and for any subsequent amendment containing information which
would alter disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be
deemed to be "filed" for the purpose of Section 18 of the Securities
Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of
that section of the Act but shall be subject to all other provisions of the
Act (however, see the Notes).

1 NAME OF REPORTING PERSON:
I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

Eli Lilly and Company
35-0470950

2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

(a)
(b)
Not Applicable

3 SEC USE ONLY

4 CITIZENSHIP OR PLACE OF ORGANIZATION

Indiana

5 SOLE VOTING POWER
NUMBER OF 889,272
SHARES

6 SHARED VOTING POWER
BENEFICIALLY OWNED BY EACH REPORTING PERSON
None

7 SOLE DISPOSITIVE POWER
889,272

8 SHARED DISPOSITIVE POWER
None

9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
889,272

10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
Not Applicable

11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
5.8%

12 TYPE OF REPORTING PERSON
CO

Item 1(a). Name of Issuer:
Ribozyme Pharmaceuticals, Inc.

Item 1(b). Address of Issuer's Principal
Executive Offices:
2950 Wilderness Place
Boulder, Colorado 80301

Item 2(a). Name of Person Filing:
Eli Lilly and Company

Item 2(b). Address of Principal Business
Office or, if None, Residence:
Lilly Corporate Center
Indianapolis, IN 46285

Item 2(c). Citizenship:
Indiana

Item 2(d). Title of Class of Securities:
Common Stock, \$.01 Par Value

Item 2(e). CUSIP Number:
76256710-5

Item 3. If this statement is filed pursuant to Rule 13d-1(b), or 13d-2(b)
or (c), check whether the person filing is a:

(a)-(j) Not applicable

If this statement is filed pursuant to Rule 13d-1(c), check
this box. [X]

Item 4. Ownership.

(a) Amount Beneficially Owned:
889,272

(b) Percent of Class:
5.8% (based on outstanding shares at January 5, 2001)

(c) Number of shares as to which the person has:

| | |
|--------------------------|---------|
| Sole voting power | 889,272 |
| Shared voting power | None |
| Sole dispositive power | 889,272 |
| Shared dispositive power | None |

Item 5. Ownership of Five Percent or Less of a Class.

Not applicable

Item 6. Ownership of More Than Five Percent on Behalf of Another Person.

Not applicable

Item 7. Identification and Classification of the Subsidiary which Acquired the Security Being Reported on by the Parent Holding Company.

Not applicable

Item 8. Identification and Classification of Members of the Group.

Not applicable

Item 9. Notice of Dissolution of Group.

Not applicable

Item 10. Certifications.

By signing below, I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

ELI LILLY AND COMPANY

By: /s/ Charles E. Golden

Charles E. Golden
Executive Vice President and Chief Financial
Officer

Date: February 8, 2001